Company Builds on Previous Observations Correlating Clinical Responses to Stem Cells with Unique B Cell Population ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced today new data and filing of a patent covering the discovery that JadiCell therapeutic activity in a model of Chronic Obstructive Pulmonary Disease (COPD) can be transferred to naïve animals by … [Read more…]

Pivotal study expected to be completed by year-end 2023 and set the stage for commercialization of PerQseal® system for large hole vessel closure Company announces €30 million strategic investment from Haemonetics as part of its previously disclosed Series D financing GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical® Limited (“Vivasure” or the “Company”), a company pioneering novel fully absorbable … [Read more…]

VENLO, The Netherlands–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide … [Read more…]

Recognition honors companies demonstrating business integrity through best-in-class ethics, compliance, and governance practices Zoetis is one of three pharmaceutical companies and the only standalone animal health company included on the list PARSIPPANY, N.J.–(BUSINESS WIRE)–$ZTS #Fortune500—Zoetis Inc. (NYSE:ZTS) has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, … [Read more…]

NEW YORK–(BUSINESS WIRE)–#ELCC2023—AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1. This oral presentation at ELCC 2023 will provide updated efficacy and safety … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Shennon Biotechnologies (“ShennonBio”), a biotech company using a proprietary single cell platform to create more effective immunotherapies, announced today the close of a $13M oversubscribed seed financing round led by DCVC, with participation from Foundation Capital, AV8 and angel investors. Founded in 2021, ShennonBio has developed a proprietary platform that can profile millions … [Read more…]

WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of the presentation will be available through a link … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia. Beginning April 1, 2023, and for the three years thereafter, IHEEZO will be … [Read more…]

Liver organ shortage puts patients at risk of death from decompensated cirrhosis with no treatment options available Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. “The goal of Kezar’s R&D … [Read more…]